Molecular-targ eted therapy for refractory immune-mediated neuropat hies

在这项研究中，我们证明了利妥昔单抗对各种难治性免疫介导的神经病的疗效和安全性。1例多灶性运动神经病(MMN)、1例慢性炎症性脱髓鞘多神经病(CIDP)、1例干燥综合征(SN)相关神经病、4例抗MAG IgM-MGUS神经病(IgM-N)患者采用OpenLabel设计，每周静脉滴注利妥昔单抗375 mg/mm2，疗程4周。减少MMN患者的IVIg总需求，虽然只是暂时的，但建议利妥昔单抗起作用。3例IgM-N患者临床状况的改善表明利妥昔单抗耐受性良好，是一种有前途的新药。所有患者均未发生不良事件。

In this study, we demonstrated the effect and safety of rituximab for various refractory immune-mediated neuropathies. Rituximab (375 mg/m^2 intravenously each week for 4 weeks) was administered in an openlabel design to one patient with multifocal motor neuropathy (MMN), one with chronic inflammatory demyelinating polyneuropathy (CIDP), one with neuropathy associated with Sjogren's syndrome (SN), and four with anti-MAG IgM-MGUS neuropathy (IgM-N). Reduction of total IVIg requirements of a patient with MMN, although the effect was only temporary, were suggested to be responded to rituximab. Improvement of clinical status in three patients with IgM-N suggeted that rituximab was well tolerated and is a promising new drug. No adverse events occurred in all patients.